Please assess the completion status of the following clinical trial:

Trial Title: Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects \>=18 years of age;~* ASA Class 1-3;~* Subjects with a Body Mass Index (BMI) of \< 35 kg/m\^2 ;~* Subjects scheduled to undergo an elective short procedure with general anesthesia requiring neuromuscular relaxation and endotracheal intubation in outpatient surgicenters;~* Subjects scheduled to undergo an elective surgical procedure expected to last 1.5 hours or less (from end of intubation to end of suturing/stapling of skin);~* Subjects who are scheduled to undergo an elective surgical procedures that allows access to the arm for TOF-Watch® SX monitoring;~* Subjects who have given written informed consent.~Exclusion Criteria:~* Subjects known to have ischemic heart disease or a history of myocardial infarction;~* Subjects in whom a difficult intubation is expected because of anatomical malformations;~* Subjects with medical conditions and/or undergoing surgical procedures that are not compatible with the use of the TOF-Watch SX (e.g., injuries to the thumbs/distal forearms, bilateral ulnar nerve damage or subjects with cardiac pacemakers);~* Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g., subjects with myasthenia gravis);~* Subjects who would require the use of pneumatic tourniquet during the surgical procedure;~* Subjects known or suspected to have significant renal dysfunction (e.g., creatinine clearance \< 30 mL per min);~* Subjects known or suspected to have significant hepatic dysfunction;~* Subjects known or suspected to have a (family) history of malignant hyperthermia;~* Subjects known or suspected to be hypersensitive to sugammadex or other cyclodextrins or rocuronium or any of its excipients;~* Subjects known or suspected to have an allergy to opiates/opioids, muscle relaxants, or other medications used during general anesthesia;~* Subjects for whom a pre-established need for post operative intensive care admission and/or hospital admission is expected;~* Subjects for whom an intra operative IV administration of fluids that contain potassium is expected;~* Female subjects who are pregnant;~* Female subjects who are breast-feeding;~* Subjects who have participated in a previous sugammadex trial;~* Subjects who have participated in another investigational drug trial within 30 days before entering into clinical trial (CT) 19.4.319 (P05700) unless pre-approved by the sponsor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Rocuronium - Sugammadex (Type: ACTIVE_COMPARATOR): Rocuronium - Sugammadex 4.0 mg/kg
- Succinylcholine (Type: ACTIVE_COMPARATOR): Succinylcholine 1.0 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete